3M AFFF Personal Injury Settlement Talks Now Run Through a Court-Appointed Mediator

There is no 3M AFFF personal injury settlement yet, but 3M told investors on October 20, 2026 that it is "actively working with a court-appointed mediator for the AFFF personal injury MDL," and its quarterly report says the court-ordered process of culling unsupported claims is now "substantially complete." For the roughly 15,250 cases still pending in MDL No. 2873 in the District of South Carolina, that combination of a mediator, a cleaned-up inventory and no trial date on the calendar is the clearest sign so far that the firefighting foam litigation has moved from fighting over who belongs in it to negotiating what the remaining claims are worth.

The disclosure came in two places on the same day. Chief executive Bill Brown made the mediator remark in closing comments on the third-quarter earnings call, and the company's Form 10-Q for the quarter ended September 30, 2026 set out the procedural history behind it: a special master appointed in June 2026, a September report recommending dismissal of most claims targeted by the first two waves of defense motions, and an order from Judge Richard M. Gergel largely adopting that report. What follows explains what 3M actually disclosed, how the claims purge worked, what it means that the talks are court-ordered and mediated, and what claimants' counsel, defendants and funders should take from a quarter in which the Mass Tort produced procedure rather than a price.

Has 3M settled the AFFF personal injury lawsuits?

No. As of October 20, 2026, 3M has not announced any settlement of the personal injury claims in the AFFF Multidistrict Litigation (MDL), and its 10-Q describes the matter only as ongoing, "court-ordered settlement discussions regarding the personal injury claims" that are "being actively facilitated by a court-appointed mediator." No settlement amount, Settlement Matrix, participation threshold or Claims Administrator has been disclosed by 3M or by the court.

That distinction matters because the AFFF litigation has already produced very large settlements, and they are routinely confused with personal injury money. In 2023, 3M agreed to pay a present value of about $10.3 billion, capped at $12.5 billion in nominal payments over 2024 to 2036, to resolve claims by public water systems, and DuPont, Chemours and Corteva agreed to a separate $1.185 billion water-system deal. Those agreements compensate utilities for testing and treating drinking water. They do not pay firefighters, military personnel or residents who allege that exposure to PFAS in aqueous film-forming foam caused kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, liver cancer or other conditions.

So the accurate summary of the 3M AFFF personal injury settlement picture on October 21, 2026 is narrow: talks are under way, they are ordered and supervised by the court, a mediator is involved, and nothing has been signed.

What did 3M say about AFFF litigation in its Q3 2026 earnings?

3M said three things that bear on the personal injury track: that it is working with a court-appointed mediator, that the court's claims-vetting process is substantially complete with tens of thousands of claims dismissed without prejudice, and that no personal injury bellwether trial has been reset. The financial statements themselves carried no new, separately identified personal injury charge.

The headline numbers were strong. 3M reported GAAP earnings of $2.63 per share, up from $1.55 a year earlier, and adjusted earnings of $2.50 per share on a new non-GAAP basis that now treats amortization of intangibles as a special item. GAAP sales were $6.6 billion, up 1.0%, and the company raised full-year adjusted guidance to $9.10 to $9.15 per share.

Q3 2026 item	Reported figure	Relevance to the AFFF litigation
GAAP EPS	$2.63 (vs. $1.55 in Q3 2025)	Boosted by a $0.60 gain on the Solventum stake, not by litigation
Adjusted EPS (new basis)	$2.50, up 12%	Excludes litigation and PFAS-exit special items
Net costs for significant litigation and PFAS exit	$0.19 per share	Same as the prior-year quarter; no step-up signaling a new personal injury accrual
GAAP sales	$6.6 billion, up 1.0%	Adjusted sales exclude manufactured PFAS products
Operating cash flow / adjusted free cash flow	$0.5 billion / $1.2 billion	CFO attributed the gap mainly to working-capital timing
2026 adjusted EPS guidance	Raised to $9.10–$9.15	Guidance carries no disclosed personal injury settlement
AFFF MDL cases pending (Oct. 1, 2026)	About 15,250	Per the 10-Q; the JPML's report shows 15,264

The $0.19 per-share line is the one claimants' counsel should read most carefully, and it says less than it seems. It bundles "significant litigation" with the costs of exiting PFAS manufacturing, and it was the same in the third quarter of 2025. A company that had reached, or expected imminently to reach, a personal injury deal of the scale this docket implies would ordinarily have to consider an accrual under the accounting rules for loss contingencies, which require one when a loss is probable and reasonably estimable. Nothing in the third-quarter materials surfaced so far shows that kind of step change. That is consistent with talks that are real but not yet at a number.

The contrast with Johnson & Johnson a week earlier is instructive. J&J booked a $5.519 billion pre-tax charge in the same reporting season because it had announced a specific ovarian talc proposal in July. 3M has announced a process, not a proposal.

Who is mediating the AFFF personal injury settlement talks?

3M has not named the mediator, and neither the earnings release nor the portions of the 10-Q available so far identify the individual; the filing says only that the discussions are "being actively facilitated by a court-appointed mediator." What can be said with confidence is who appointed that person and why it matters.

The mediator is court-appointed, not privately retained, and the talks are court-ordered. In an MDL, that structure gives the transferee judge, here Judge Gergel, continuing visibility into whether the parties are engaging, and it gives the judge leverage over scheduling. Secondary reporting from mid-2026 described Judge Gergel pressing 3M, DuPont, BASF, Johnson Controls and other defendants to resolve personal injury claims before any bellwether reaches a jury. A court-appointed mediator is the formal machinery for that pressure.

Judge Gergel has used this playbook before in this same MDL. The water-system settlements were reached on the eve of the first scheduled bellwether trial in June 2023, involving the City of Stuart, Florida, after the court had denied key defense motions and kept the trial date firm until the parties reached terms. The personal injury track differs in one important respect: there is currently no trial date to hold firm.

It is also worth separating the mediator from the Special Master. The special master appointed in June 2026 was tasked with handling the defense motions to dismiss deficient claims, an adjudicative and administrative role. The mediator's job is to broker a deal. Nothing in the public record ties the two roles to the same person.

How the AFFF claims purge worked: from CMO 37 to the special master

The vetting that 3M now calls "substantially complete" ran on a court order entered eight months earlier. Case Management Order No. 37, filed February 25, 2026 (ECF 8876), created a non-compliance list procedure. Defendants could identify plaintiffs who had not served a required profile form, the AFFF analogue of a Plaintiff Fact Sheet (PFS), or, for plaintiffs subject to the court's earlier CMO 35, medical records showing a qualifying diagnosis.

A plaintiff on the list then had 14 days from service, plus any agreed extension, to cure by uploading compliant materials through the "Plaintiff Cure" tab of the MDL portal. The evidentiary bar for the diagnosis requirement was deliberately low: CMO 37 says it can be satisfied by any medical or insurance record indicating that the plaintiff was diagnosed with the alleged injury or has a past medical history of it. The order did not demand expert support, exposure proof or causation evidence; it demanded proof that the claimed disease exists.

That makes CMO 37 a records-production order rather than a full Lone Pine Order. A classic Lone Pine order requires each plaintiff to come forward with prima facie expert evidence of exposure and causation on pain of dismissal. CMO 37 asked for something more basic, and that is why the scale of what followed is striking.

According to tracker reports, defendants served motions in June 2026 naming more than 8,000 plaintiffs and then a further wave naming more than 10,000, and they withdrew requests as to more than 1,000 plaintiffs after cure submissions came in. Judge Gergel appointed a special master in June 2026 to work through the motions. In September 2026, according to 3M's 10-Q, the special master issued a report and recommendation on the first two sets of motions recommending that most of the claims subject to them be dismissed, and the court largely adopted it.

How many AFFF lawsuits were dismissed in 2026?

3M's 10-Q puts the number at "tens of thousands of claims" dismissed without prejudice, while a plaintiff-side tracker reports a September 28, 2026 order dismissing roughly 13,226 claims, and other reporting describes a recommendation covering about 13,000 plaintiffs. The figures measure different things and should not be treated as contradictory.

Three counting conventions are at work in the AFFF docket:

1. Cases versus claims. The Judicial Panel on Multidistrict Litigation (JPML) counts civil actions. One action can include many plaintiffs, and one plaintiff can assert more than one injury. The JPML's October 1, 2026 report shows 15,264 pending actions (trackers put the total ever docketed at 19,840), and 3M's 10-Q gives about 15,250 cases as of the same date. A figure in the tens of thousands of claims is therefore compatible with a pending case count in the mid-teens of thousands.
2. One order versus the whole process. The 13,226 figure is reported for a single September order. 3M's "tens of thousands" describes the cumulative result of the court-mandated vetting process.
3. Filed versus unfiled. Large MDLs often carry claims in a Census Registry or tolling arrangement outside the formal case count. The 10-Q excerpts available do not say whether unfiled claims were affected.

The safest statement is the one 3M itself makes: the vetting removed a very large number of claims, without prejudice, and what remains is a smaller, documented inventory. Until the special master's report and the adopting order are publicly available in full, any precise total beyond 3M's own description should be treated as approximate.

Can a dismissed AFFF claim be refiled?

In principle, yes: a dismissal without prejudice does not adjudicate the merits, so a plaintiff who later obtains the missing profile form or diagnosis record is not barred by the dismissal itself from bringing the claim again. In practice, the Statute of Limitations is the real constraint.

Most states run the limitations period for a toxic-exposure personal injury claim from discovery of the injury and its probable cause, under some version of the Discovery Rule. A plaintiff who filed within that window, was dismissed without prejudice for paperwork, and now refiles may find that the window has closed in the meantime. Whether the original filing tolls the period depends on state savings statutes, which vary considerably, and on any Tolling Agreement the plaintiff's firm negotiated with defendants. Some secondary sources also note that refiling restrictions in MDL orders can turn a without-prejudice dismissal into a de facto final one; the precise terms of the September orders on refiling have not been publicly summarized in anything reviewed for this article.

For a firm holding dismissed clients, the practical questions are therefore immediate and client-specific: what the governing state's limitations and savings rules are, whether a tolling agreement covers the client, and whether the missing record can actually be obtained. A claimant who never had a qualifying diagnosis is not helped by the without-prejudice label at all.

When is the next AFFF bellwether trial?

There is no personal injury Bellwether Trial on the calendar in MDL No. 2873 as of October 21, 2026. The first trial, built around kidney cancer plaintiffs and set for October 2025, was vacated in August 2025 and has not been reset. Corteva has told investors that it expects the first personal injury bellwether trial to be scheduled for 2027.

Date	Event in the AFFF personal injury track
June 2023	3M agrees to the public water system settlement ($10.3 billion present value) before the first water-provider bellwether
December 2023	Parties select an initial pool of 25 personal injury bellwether plaintiffs
July 2024	Court selects nine of the 25 for further discovery
April 2025	Court adds three plaintiffs to the pool
May 2025	Court indicates the first trial will involve one or more of three kidney cancer plaintiffs
August 2025	October 2025 kidney cancer bellwether trial vacated; no new date set
February 25, 2026	CMO 37 sets the non-compliance list and 14-day cure procedure
April 2026	General Causation expert discovery on liver cancer and thyroid cancer closes
June 2026	Defense motions to dismiss deficient claims; special master appointed
July 30, 2026	CMO 26O reportedly resets Group B (thyroid disease, ulcerative colitis) bellwether proposals
August 2026	Defendants move to exclude certain liver and thyroid cancer causation experts; motions pending
September 2026	Special master recommends dismissal of most challenged claims; court largely adopts
October 20, 2026	3M discloses court-appointed mediator and "substantially complete" vetting
November 20, 2026	Reported deadline for Group B bellwether-selection and expert-discovery proposals

Two pending tracks deserve attention. First, the defense motions to exclude plaintiffs' liver and thyroid cancer experts, filed in August 2026, are the AFFF equivalent of a Daubert Challenge under Federal Rule of Evidence 702. A ruling excluding those experts would remove whole injury categories from the settlement table; a ruling admitting them would strengthen plaintiffs' hand on exactly the injuries that have not yet had a trial pool. Second, the Group B process for thyroid disease and ulcerative colitis, which trackers report is governed by CMO 26O with proposals due November 20, 2026, keeps a second wave of injuries moving toward trial readiness even while the first wave is stalled.

How much will the 3M AFFF personal injury settlement be worth?

No one outside the negotiation knows, and no figure has been disclosed by 3M, any other defendant, plaintiffs' leadership or the court. Per-claim payout ranges circulating on law firm marketing pages are projections, not reported terms, and none of those reviewed for this article cites a court filing or company disclosure.

What the record does show is the shape of the inputs. The inventory has shrunk because of vetting, which lowers defendants' gross exposure but raises the average quality of the remaining claims. Injury categories differ sharply in the strength of their scientific support: kidney cancer and testicular cancer have been the lead injuries in the bellwether pool, while liver and thyroid cancers face pending Rule 702 challenges. And there are multiple manufacturers. 3M is the largest AFFF maker, but DuPont, Chemours, Corteva, BASF, Tyco/Johnson Controls and others are also defendants, so any Global Settlement is likely to involve allocation among defendants as well as among injuries, as the water-system deals did.

Practitioners modeling outcomes should treat the $10.3 billion water deal as a ceiling on nothing and a precedent for structure only: it was a class settlement paid over more than a decade with amounts tied to testing results, which is a different instrument from an inventory-based personal injury program with a points grid.

Why vetting comes before a 3M AFFF personal injury settlement

The sequence 3M disclosed, first clean the inventory and then mediate, is the standard choreography of late-stage mass tort resolution, and it explains why the October 20 disclosures are significant even without a number.

A defendant cannot price a global deal while it does not know how many claimants have a diagnosed, compensable injury. Plaintiffs' leadership, for its part, cannot credibly promise participation rates while a large share of the docket may not survive basic proof requirements. Records-based vetting orders such as CMO 37 solve both problems: they convert a headline case count into a verified population. The paraquat MDL followed a similar path toward a settlement program built on documented claims, and the Camp Lejeune litigation shows how much of a resolution's friction comes from proving diagnosis and exposure at scale.

Mediation at this point also shifts leverage. With the inventory verified and no trial date to fear, defendants gain time; plaintiffs, conversely, gain a docket that is harder to dismiss as inflated. Judge Gergel's history in the water-system phase suggests that he will use the Rule 702 rulings and the Group B schedule to create the deadline that a trial date would otherwise supply.

How the personal injury track differs from the water settlements

The two tracks share an MDL and a judge but almost nothing else.

Feature	Public water system settlements	Personal injury track
Claimants	Utilities and public water systems	Individuals (firefighters, military, residents)
Status	Final approval; payments under way	No settlement; court-ordered mediation
3M amount	$10.3 billion present value, up to $12.5 billion nominal	Not disclosed
DuPont/Chemours/Corteva amount	$1.185 billion	Not disclosed
Payment period	2024 to 2036 for 3M	Not applicable
Proof required	Testing results and treatment costs	Diagnosis, exposure, causation
Procedural vehicle	Rule 23 settlement class	Expected inventory or matrix program
Key gate	First water-provider bellwether (June 2023)	Vetting (2026), Rule 702 rulings, Group B schedule

The September 10, 2026 North Carolina agreement by Chemours, DuPont and Corteva, resolving claims by the state and 11 local entities over discharges from the Fayetteville Works plant with 15 years of payments carrying a net present value of about $355 million, belongs to the governmental and environmental side of the ledger, not the personal injury track.

What it means for PI firms, claimants, defendants and funders

For personal injury firms holding AFFF dockets. The vetting phase is functionally over, so the inventory each firm will bring to the table is largely fixed. Firms should expect any eventual program to demand the same diagnosis documentation CMO 37 required, and more on exposure history, and should be reconciling which clients were dismissed, which cured, and which remain. Referral and co-counsel arrangements built on headline case counts may need to be revisited where a large fraction of referred claims did not survive. Allocation questions under the Common Benefit Fund will also sharpen once a gross figure exists.

For claimants. A claimant whose case remains pending has, by definition, cleared the records threshold. A claimant who was dismissed without prejudice should be asking counsel specifically whether refiling is possible under the state's limitations rules. Anyone weighing a new AFFF claim now faces a more demanding baseline: a documented diagnosis from the outset. Questions about Medical Lien recovery by health plans and government payers will matter for net payouts in any program, as they do in every large mass tort settlement.

For defendants. 3M's disclosure language sets the public baseline: talks, mediation, no accrual signal. Co-defendants will be measured against it in their own quarterly filings over the coming weeks, and Corteva's 2027 trial expectation already gives the defense side a stated timeline. The pending Rule 702 motions are the biggest near-term variable for valuation.

For litigation funders. Third-Party Litigation Funding exposure in AFFF portfolios is now easier to value case by case, because the surviving inventory is documented. Funders with positions in dismissed claims face a recovery problem that turns on refiling rules. Funding-disclosure orders in other MDLs this fall indicate that transferee courts are also paying closer attention to who finances mass tort inventories.

What to watch next

• The Rule 702 rulings on liver and thyroid cancer causation experts, pending since August 2026.
• November 20, 2026, the reported deadline for Group B bellwether-selection and expert-discovery proposals.
• Co-defendant quarterly filings, especially DuPont, Chemours and Corteva, for matching or diverging descriptions of the mediation.
• Publication of the special master's report and the adopting order, which would allow a precise count of dismissed claims and the terms governing refiling.
• Any accrual tied to a 3M AFFF personal injury settlement in the company's fourth-quarter or annual filings that is broken out from the "significant litigation and PFAS exit" line, which would be the first financial signal of a price.

FAQ

Has 3M settled the AFFF personal injury lawsuits?

No. As of October 2026, 3M has not settled the AFFF personal injury claims; it disclosed on October 20, 2026 that court-ordered settlement discussions are under way with a court-appointed mediator in MDL No. 2873.

Who is mediating the AFFF personal injury settlement talks?

The mediator has not been publicly named. 3M's filing says only that the court-ordered talks are being facilitated by a court-appointed mediator in the District of South Carolina, where Judge Richard M. Gergel oversees the MDL.

How many AFFF lawsuits were dismissed in 2026?

3M says tens of thousands of claims were dismissed without prejudice through the court's claims-vetting process, and trackers report that a single September 28, 2026 order dismissed roughly 13,226 claims for missing fact sheets or diagnosis records.

When is the next AFFF bellwether trial?

No personal injury bellwether trial is scheduled. The October 2025 kidney cancer trial was vacated, and Corteva has said it expects the first personal injury bellwether to be scheduled for 2027.

Does the $10.3 billion 3M PFAS water settlement cover personal injury claims?

No. The $10.3 billion settlement resolves claims by public water systems for drinking-water contamination; it does not compensate individuals for cancer or other injuries, which remain pending in the personal injury track of the AFFF MDL.